Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $91 to $89.
Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $89
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.